Current and Emerging Drug Delivery Needs in Oncology

Drug Delivery Needs in Oncology

Due to the increasing number of parenteral biologic therapies that are administered intravenously, the already high pressure on infusion capacity and healthcare resources is expected further increase. A change from intravenous to subcutaneous dosing has been shown to reduce dosing complexity and overall drug administration related costs. There is keen interest in technologies that facilitate subcutaneous administration and potentially enable drug administration in the home setting. 

• Led by: Beate Bittner, PhD

 Portfolio Strategy Director, Roche 

• Panelists: Panel: H Janice Adkins, MBA

Associate Director Marketing, BD Medical The exp Pharmaceutical Systems, North America EMEA

• Ulrich Bruggemann

Head Academics and Innovation, Global Medical Devices of the Development, Sanofi US

• Shawn Davis, PhD

Director, Technology Strategy and Innovation, Amgen

• Declan Reilly

Section Head, Device Engineering, Device Development PTDE-D, Roche

• Andrew J Yee, MD Medical Oncologist, Massachusetts General Hospital Cancer Center 

This presentation took place at the 7th Annual Partnership Opportunities in Drug Delivery (PODD) 2017.